Laboratory Methods Sample Clauses

Laboratory Methods. ELITE will ensure that all components and in-process release testing used to manufacture the Product(s) meets the specifications. At least one test (ID) to verify the identity of each batch of incoming material will be conducted. A supplier C of A or C of C may be referenced instead of performing other tests, provided that a supplier evaluation program is in force. ELITE’s internal Quality unit will approve all test results.
AutoNDA by SimpleDocs
Laboratory Methods. Laboratory work will include standard processing and cataloguing of the materials recovered in the field, and special studies to address the program’s research issues.
Laboratory Methods. The official laboratory shall use methods that comply with Article 34 of Regulation (EU) 2017/625.
Laboratory Methods. Laboratories shall use methods that comply with Article 11 of Regulation (EC) No. 882/2004. Laboratories performing the same analysis should use consistent methods to ensure comparability and consistency of results nationally.
Laboratory Methods. Laboratory procedures for this project included two components: 1) instrument calibration, testing and preparation, and 2) analysis of sediment and water samples from the field site. All instrumentation was calibrated, prior to deployment, by the Coastal Studies Institute Field Support Group in their testing facilities. Since optical backscatter sensors are more sensitive to fine than to coarse sediment, while the reverse is true for acoustic systems, appropriate field conversion factors were established using bottom sediment from the study sites. This procedure consisted of exposing the sensors to a series of uniformly-stirred mixtures of distilled water and known concentrations of field sediment. The voltage output from the sensors was then related to the sediment concentration by using regression to fit a calibration curve to a scatter-plot of these variables. Since the field data from the optical backscatter sensors were ultimately found to be faulty, OBS calibration results will not be discussed. Field data from the ADV’s appeared to be reliable, however, and as such, the electronic signal strength was converted from the calibration curve obtained in the laboratory, which took the form: C=7.20197 x 10-10 (10 0.043SS) (3.1) where C is the volumetric concentration of sediment and SS is the ADV signal strength. Dry sieving at 0.25 φintervals was conducted to determine the grain-size composition of the samples of bottom sediment. The water samples, collected at the surface and at 0.5, 2 and 4 m above the bed, were filtered through 0.7-m paper using a pump-operated filtration system, dried in an oven at 60oC, and weighed to determine the sediment concentration. Data Processing and Analytical Methods
Laboratory Methods. The official laboratories shall use methods that comply with Article 34 of Regulation (EU) 2017/625. Official laboratories within the Food Safety Laboratory Service performing the same analysis should strive to use comparable methods to ensure consistency of results nationally or adopt other strategies to ensure this consistency. Where similar methods are undertaken, there should also be consistency with regard to the sample quantities requested by the Food Safety Laboratory Service, sample storage and preparation.
Laboratory Methods. Materials collected during field work will undergo a variety of laboratory analysis to address the research questions. The types of analysis conducted will be dependent on the artifacts and samples collected during field work, but may include radiocarbon dating of charcoal and bone samples, x-ray fluorescence, and hydration analysis if obsidian artifacts are collected; studies of faunal material (e.g., species identification, evidence of butchering or modification); studies of macrobotanical remains from flotation samples; lithic analysis (e.g., identifying artifacts as diagnostic to specific cultures and/or time periods, identifying raw materials represented among the assemblage); and trace element analysis of copper, if any is identified during the investigations. Though not exhaustive, examples of analyses to be conducted as part of data recovery are provided below.8 The specific types of analyses will be refined in the amended Treatment Plan. Flaked Stone Artifacts Flaked stone analyses should have two main objectives: documenting the flaked stone assemblages at sites/loci, and identifying the kinds of lithic-reduction activities that occurred there. Toward this end, archaeologists will measure and weigh all formed tools, record edge type and modification, and document tool condition (e.g., whole, distal fragment, margin). Debitage samples from single component areas will receive technological analysis designed to identify the types of flaking debris and reduction activities represented at different sites. Analysis may also include identifying procurement sources for the lithic material. Other Artifacts A variety of other artifacts, including beads, ornaments, bone implements/tools, quartz crystals, ceramics, and perishable remains (e.g., cordage, basketry), may also be recovered during the course of the Project. If beads are encountered, archaeologists will record material, color, basic measurements that include length and width (or diameter), thickness (or curvature), and perforation size and type (e.g., conical, biconical, conical with retouch from the opposite side). Additional observations will include the material employed, details of manufacture (e.g., wire- wound, edge ground, scored and snapped), condition, color and tinge, and whether or not the piece appears to have been worn (e.g., asymmetrical wear of the perforation or evidence of polish). Archaeologists will measure bone tools and sort them into functional categories based on their morph...
AutoNDA by SimpleDocs

Related to Laboratory Methods

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Payment for Labor and Materials The Contractor agrees and binds itself to pay for all labor done, and for all the materials used in the construction of the work to be completed pursuant to this contract.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Manufacturing Costs Patheon shall be allowed to adjust the Fees: (i) for costs associated with the conversion of Granulations and Components into Drug Product (the “Conversion Costs”) in respect of the Drug Product based on the most recently available final Producers’ Price Index for Pharmaceutical Product as published by the U.S. Bureau of Labor Statistics or any governmental successor thereto (“PPI”) using the procedure set forth in Section 4.3 and (ii) for Component Costs to pass on the actual amount of any increase or decrease in such costs without xxxx-up. For each Contract Year in which Patheon is entitled to adjust the Fees Patheon shall provide Client with written notice of any change in the Fees within 30 days of receipt by Patheon of the Annual Forecast. The Parties agree that the Fees shall not be adjusted more than once per Contract Year, however this limitation shall not include price adjustments under section 4.3 or 4.4. In addition, notwithstanding anything herein to the contrary, Manufacturing Fees associated with Conversion Costs shall not be increased by greater than [***]% per annum in any Contract Year during the Term. There shall be no similar limitation in terms of increases in Component Costs which shall be passed on to Client in an amount equal to the actual increase paid by Patheon without markup.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.